"University Health Texas Diabetes Institute offers high-quality healthcare services to adults including chronic disease management, preventive care and treatment for minor illnesses. Our Pharmacy offers free walk-in COVID-19 vaccinations including 1st dose and 2nd dose for people 12 and older, and 3rd dose and booster shots for those currently eligible, Monday – Friday 8 a.m. – 5 p.m."

During the past decade, Texas Diabetes Institute conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 4 clinical trials were completed, i.e. on average, 36.4% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 1 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Diabetes Institute" #1 sponsor was "The University of Texas Health Science Center at San Antonio" with 15 trials, followed by "Boehringer Ingelheim" with 1 trials sponsored, "Fractyl Laboratories, Inc." with 1 trials sponsored, "GMP Endotherapeutics" with 1 trials sponsored and "Mannkind Corporation" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Diabetes Institute" #1 collaborator was "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 7 trials as a collaborator, "American Diabetes Association" with 1 trials as a collaborator, "Amylin Pharmaceuticals, LLC." with 1 trials as a collaborator, "Doris Duke Charitable Foundation" with 1 trials as a collaborator and "Emissary International LLC" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Texas Diabetes Institute" are "Type 2 Diabetes" (4 trials), "Diabetes" (3 trials), "Diabetes Mellitus, Type 2" (3 trials), "Hypoglycemia" (2 trials) and "Type 2 Diabetes Mellitus" (2 trials). Many other conditions were trialed in "Texas Diabetes Institute" in a lesser frequency.

Most popular intervention types in "Texas Diabetes Institute" are "Drug" (17 trials), "Other" (3 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Atropine" (2 trials), "Exendin-(9-39)" (2 trials), "Pioglitazone" (2 trials) and "Beta-hydroxy-butyrate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Texas Diabetes Institute" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Texas Diabetes Institute". undefined are not yet recruiting, 8 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Texas Diabetes Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Texas Diabetes Institute, 4 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 2 trials that are defined as “Not Applicable".